Weight Loss Drugs

Novo Nordisk Eli Lilly Eli Lilly Zepbound Market Competition Zepbound GLP-1 Medications Compounded Drugs Ozempic Orforglipron Wegovy Roche Compounded Semaglutide Mounjaro and Zepbound Viking Therapeutics

4 ARTICLES

3mo ago

Novo Holdings Reports Record Income Despite Novo Nordisk's Market Decline

The investment arm of Novo Nordisk doubled its 2024 income to €8 billion, driven by obesity drug dividends, while focusing on Asian expansion to counter challenges.

9 ARTICLES

4mo ago

Domino's Faces Mixed Earnings Report with U.S. Sales Lagging Expectations

3 ARTICLES

5mo ago

Allurion Technologies Stock Surges Following New Obesity Treatment Study Announcement

19 ARTICLES

8mo ago

Novo Nordisk Expands Wegovy Supply Amid Compounding Drug Concerns

4 ARTICLES

11mo ago

Roche Accelerates Development of Promising Weight-Loss Pills

8 ARTICLES

11mo ago

Viking Therapeutics Advances Weight-Loss Drug, Shaking Up Market Leaders